Funds and ETFs Knight Therapeutics Inc.

Equities

GUD

CA4990531069

Pharmaceuticals

Market Closed - Toronto S.E. 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
5.73 CAD +0.70% Intraday chart for Knight Therapeutics Inc. +0.17% +10.40%

ETFs positioned on Knight Therapeutics Inc.

Name Weight AuM 1st Jan change Investor Rating
0.19% 11 M€ -.--%
0.01% 773 M€ -.--% -
Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.73 CAD
Average target price
6.729 CAD
Spread / Average Target
+17.43%
Consensus
  1. Stock Market
  2. Equities
  3. GUD Stock
  4. Funds and ETFs Knight Therapeutics Inc.